The profile is currenly unclaimed by the seller. All information is provided by CB Insights.


Dead | Dead

Total Raised


About EnCoate

EnCoate develops , cost effective, food-grade biopolymer technologies. These simple biopolymers have broad application in extending the shelf-life of food, pharmaceutical and agricultural products (such as probiotics) at ambient temperatures.

EnCoate Headquarter Location

PO Box 5636 Wellesley Street

Auckland, 1141,

New Zealand


Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Latest EnCoate News

Venture capital deal brings probiotics in

Aug 9, 2019

Wednesday, 13 June 2007, 10:07 am 13 June, 2007 EnCoate, the 50/50 owned AgResearchand Ballance Agri-Nutrients Joint Venture Company, todayannounced it is close to signing a multi-million dollar dealthat will see an injection of venture capital money tofinance the development of a revolutionary line of probioticformulations that will enhance food products. Once theagreement is signed EnCoate will receive $6.3 million ininvestment from one of Australasia’s biggest life sciencesventure capital funds. Probiotics are microbes that havebeneficial health effects on humans and animals. However,current technology limits their application to yoghurt andother milk products as they must be refrigerated. EnCoate’s goal is to extend the shelf-life ofprobiotics to two years at room temperature and humiditywith special formulations. Current technology does not allowprobiotics to be mixed with other ingredients, whichconsiderably limits the scope of their application. EnCoatehas developed a technology that can stabilise these microbesso they can be used to enhance foods such as breakfastcereals, infant milk-powders and dog-biscuits. BridgitHawkins, Acting EnCoate CEO, says this opens a potentiallyhuge global market for probioticingredients. “Probiotics have been recognised for manyyears as giving significant health benefits. Until nowconsumers have been strictly limited to a small range ofproducts offering the benefits of probiotics.” Thetechnology was developed by a team of scientists atAgResearch’s Lincoln campus near Christchurch and led byDr Trevor Jackson of the Crown Research Institute’sBiocontrol, Biosecurity & Bioprocessing Section. BridgitHawkins says the start-up phase of the business involveddeveloping the science, looking at proof of concept, lookingfor business opportunities and engaging with end users toensure the technology was appropriate. “This involveddeveloping what is known as a biopolymer coating that hadfirst been used in the production of biological controlagents in agriculture. The first commercial product to usethis technology was for the control of grass grub. It hasbeen commercially available in the marketplace for someyears. “With the new probiotics opportunity, thebusiness is now positioned ahead of its competition and isan attractive investment proposition,” says BridgitHawkins. “What’s more, EnCoate has potential beyondextending the shelf life of probiotics, with the coretechnology behind EnCoate being the biopolymer, which hasapplications including in agricultural biology, food andseed coatings, and vaccines.” AboutEnCoate EnCoate is a joint venture company between NewZealand’s leading fertiliser company, BallanceAgriNutrients Limited and AgResearch Limited, NewZealand’s primary sector Crown Research Institute. EnCoatespecialises in the development of proprietary food-gradebiopolymer technologies. These simple biopolymers have broadapplication in extending the shelf-life of food andmicrobe-based agricultural and health products at up toambient temperatures. Additional technologies include fungaland bacterial products and deliverysystems. About Ballance Agri-Nutrients Ballance Agri-Nutrients is New Zealand’s leadingfertiliser specialist, with manufacturing plants located inWhangarei, Mount Maunganui and Invercargill. In addition,the company owns the ammonia-urea manufacturing plant atKapuni in Taranaki, and Super Air, one of the country’slargest agricultural aviation companies. Ballance is a100-percent farmer-owned co-operative, with some 18,000shareholders throughout New Zealand. It was officiallylaunched in 2001, bringing together a number of regionalfertiliser co-operatives to become a truly national company.The company places a strong emphasis on delivering value toits shareholders and on the use of a scientific approach toplant nutrient management. AboutAgResearch Ltd New Zealand’s largest Crown ResearchInstitute, AgResearch comprises a number of renownedresearch centres but most importantly it is made up ofhundreds of individual scientists, technicians, their teamsand support staff. Their work targets the key issues facedby the pastoral and biotechnology sectors, and leads toinnovative products and knowledge that benefit all NewZealanders. Through its mission, 2020 Science, AgResearchendeavours to keep the country prosperous to 2020 andbeyond. The strategy is underpinned by its five big ideas :to double the value of dairy production while halving thecosts and impacts on the environment; to double the value ofmeat and textile production while halving the costs andimpacts on the environment; reducing the risk of pests anddiseases gaining a foot-hold in New Zealand and helping tomanage those already here; working with rural communitiesand agribusinesses to ensure they both remain sustainablefor future generations in a global environment; and makingthe most of opportunities beyond food and fibre. The OECD area employment rate – the share of the working-age population with jobs – fell by 4.0 percentage points, to 64.6%, in the second quarter of 2020, its lowest level since the fourth quarter of 2010. Across the OECD area, 560 million persons ... More>> Spark turned on 5G in downtown Auckland today and has partnered with Auckland Transport (AT) to showcase some of the latest in IoT (Internet of Things) technology and demonstrate what the future could look like for Auckland’s CBD with the power of 5G. 5G is ... More>> Since the border closed in late-March 2020, net migration has averaged about 300 a month, Stats NZ said today. In the five months from April to August 2020, overall net migration was provisionally estimated at 1,700. This was made up of a net gain ... More>> Lake Tasman, New Zealand | 2016 | Photo: Dr Jenna Sutherland Meltwater lakes that form at glacier margins cause ice to recede much further and faster compared to glaciers that terminate on land, according to a new study. But the effects of these glacial ... More>> ALSO:

  • Where is EnCoate's headquarters?

    EnCoate's headquarters is located at PO Box 5636, Auckland.

  • What is EnCoate's latest funding round?

    EnCoate's latest funding round is Dead.

  • How much did EnCoate raise?

    EnCoate raised a total of $4M.

  • Who are the investors of EnCoate?

    Investors of EnCoate include Inventages Venture Capital.

  • Who are EnCoate's competitors?

    Competitors of EnCoate include HTG Molecular Diagnostics, WaferGen Bio-systems, Life Technologies Corporation, Crossject Medical Technology, Lipomics Technologies and 11 more.

You May Also Like

Solidus Biosciences Logo
Solidus Biosciences

Solidus Biosciences is a company that received a STTR Phase II grant for a project entitled: Development of a Lead Optimization Chip for Drug Discovery. Their award is funded under the American Recovery and Reinvestment Act of 2009 and their project will address further development and commercialization of a multi-enzyme lead optimization chip (Multizyme Chip) for high-throughput generation of lead compound analogs coupled with cell-based screening for the rapid identification of biologically active derivatives. Such a capability directly impacts a key bottleneck in drug discovery; namely, the efficient optimization of lead compounds to develop drugs with optimal pharmacological properties. Solidus Biosciences, Inc. proposes to combine six biocatalysis with pharmacological screening to provide rapid identification of biologically active compounds against cell-specific targets, which is a new paradigm for lead optimization. Moreover, the Multizyme Chip platform will be well-suited for lead optimization in related industries, including agrochemicals, cosmetics, and cosmeceuticals. The Solidus technology will thus improve the competitiveness and efficiency of the pharmaceutical, cosmetics, and chemical industries, and will serve as a rich source of new and improved commercial products. The broader impacts of this research are the advances that Solidus Biosciences will achieve toward generating better and safer drugs, reducing the cost to develop these drugs, and increasing the overall efficiency of the pharmaceutical industry. Solidus will generate Multizyme Chips for purchase by pharmaceutical and biotechnology companies to facilitate their lead optimization programs, particularly those involving natural product-derived and complex synthetic small molecule leads. Cryopreservation techniques developed in Phase II will enable the sale of chips and chip-handling devices produced during Phase I, and will allow seamless penetration of the Solidus technology platform into the company's target markets. Solidus Biosciences is a company that received a STTR Phase I grant for a project entitled: Development of a Lead Optimization Chip for Drug Discovery. Their research project aims to develop a new method for generating lead compounds by using enzymatic modification of compound sets. Availability of new methodology to generate biologically active compounds from existing molecules may enhance the success of the drug discovery process and may lead to the discovery of new and useful therapeutics. Solidus Biosciences is a company that received a STTR Phase I grant for a project entitled: High-Throughput RNAi Screening of Mammalian Cells. Their research project aims to develop a system for the rapid screening of siRNAs that can inhibit genes involved in cellular responses such as hyperosmotic stress that can affect pathways of high commercial importance, including protein production. Use of hyperosmotic stress as a proof of concept system will demonstrate the feasibility of high-throughput RNAi screening and will at the same time yield results that can be used to improve monoclonal antibody production in commercial and laboratory settings Production of biopharmaceuticals such as antibodies is exquisitely responsive to the culture conditions under which the cells are grown and thus can be improved through optimizing such settings, which in turn, would affect the genes involved in the specific synthetic pathways of interest. Development of a rapid methodology to identify inhibitory RNA molecules that can inhibit genes that adversely affect yield would be of significant importance to pharmaceutical companies that produce protein therapeutics and may result in a lowering of the const of these therapeutic entities.


Nanosep is a company with a new high performing environmentally friendly analytical technology to be used in the pharmaceutical and biotech industry. With the Nanosep technology, a customer can easily get results from complicated samples, such as blood plasma and pharmaceutical products. Both faster, with less effort and with higher precision compared to technologies available on the market today

Sistemic Logo

SistemRNA is a healthcare company developing a microRNA-based platform that screens compound databases against the microRNA expression profiles of leading drugs, to find compounds with similar profiles. Per Sistemic, this process generates information on biological differences, mechanism of action and potential new targets.


Proteoplex is a spinout of Incyte Genomics and aims to provide the scientific community with key functional genomic and proteomic tools and services in the areas of Gene Expression, Protein Expression and Cell-Based Assays. The proteomics product addresses a major barrier in defining the function of proteins in cells; how to quickly and cheaply test thousands of samples for the presence of a particular set of proteins. This protein product will be closely followed by the launch of gene expression products to solve a similar barrier in the genomics market; how to quickly and cheaply interrogate thousands of samples against a defined set of important genes.


SideroGen, Inc. is focused on the development and manufacture of biomolecule purification products for applications in the fields of forensic science and clinical genomics. These products will be developed for processing very small samples, common to forensic science and cancer diagnostics. The core technology for these products is based on inert ferro-ceramic, paramagnetic particles of compositions that are specifically designed to be compatible with downstream DNA and protein analysis. This technology and its uses are exclusively owned and were developed by SideroGen, Inc.

Van Andel Institute Logo
Van Andel Institute

VARi has several research programs in basic sciences that will improve our understanding of the cancer process, including programs rich in functional genomics. They have a long-term commitment to the development of programs that facilitate the translation of these basic science discoveries into therapeutic strategies for attacking cancer and thus improving human health.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.